Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
AZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range9,670.00p - 13,388.00p
Previous CloseN/A
Volume91.53K
Average Volume (3M)3.10M
Market Cap
£177.58B
Enterprise Value183.25B
Total Cash (Recent Filing)$5.49B
Total Debt (Recent Filing)$30.11B
Price to Earnings (P/E)32.7
Beta1.12
Next Earnings
Apr 29, 2025EPS Estimate
170.44Last Dividend Ex-Date
Feb 20, 2025Dividend Yield2.12%
Share Statistics
EPS (TTM)3.56
Shares Outstanding1,550,607,200
10 Day Avg. Volume2,238,407
30 Day Avg. Volume3,099,384
Financial Highlights & Ratios
PEG Ratio2.18
Price to Book (P/B)N/A
Price to Sales (P/S)4.31
Price to Cash Flow (P/CF)18.50
P/FCF Ratio25.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda10.64
Forecast
1Y Price Target
13,797.25pPrice Target Upside20.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Market PotentialAstraZeneca flags a potential $5 billion+ total peak sales for Baxdrostat, with significant differentiation on longer half-life and no drug-drug interactions.
Product DifferentiationPositive Phase III data for eneboparatide was released, indicating potential for differentiation in the treatment of hypoparathyroidism.
Sales GrowthThe valuation looks attractive, and the mid-term guidance implies high-single-digit sales growth, supporting a potential increase in stock price.
Bears Say
Clinical ConcernsThere are concerns about the high rate of anti-drug antibodies found in prior studies, which could increase further in longer studies.
Competitive PressureNo cognitive benefit was observed with eneboparatide, which is a key quality-of-life symptom in hypoparathyroidism, and its competitor shows significant cognitive benefits.
Safety IssuesSafety remains a debate with stomatitis/mucositis and now with one ILD-related death.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.03% Insiders
13.59%
Mutual Funds
0.01% Other Institutional Investors
77.34% Public Companies and
Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9670.00p and its highest was 13388.00p in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is £177.58B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Apr 29, 2025 which is in 34 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Feb 06, 2025. The company reported 1.618p earnings per share for the quarter, beating the consensus estimate of 1.602p by 0.015p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 167.999p which represents an annual dividend yield of 2.12%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 170.44.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,607,200 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.618p in its last earnings report, beating expectations of 1.602p. Following the earnings report the stock price went up 5.932%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
13,797.25p (20.48% Upside)
13,797.25p (20.48% Upside)
Insider Transactions
Bought Shares
Worth £151.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.52%
12-Months-Change
Fundamentals
Return on Equity
17.43%
Trailing 12-Months
Asset Growth
4.72%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
---
AZN Stock 12 Month Forecast
Average Price Target
13,797.25p
▲(20.48% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
25/29 ratings generated profit
1 Year Average Return
+14.70%
reiterated a buy rating 9 days ago
Copying Matthew Weston's trades and holding each position for 1 Year would result in 86.21% of your transactions generating a profit, with an average return of +14.70% per trade.
---